Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Krishnan K. Mahadevan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6503-6851; OpenAlex author ID A5077713171. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. First author DOI 10.1038/s44318-026-00854-5↗
  2. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  3. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
  4. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Co-author DOI 10.1126/science.adh4567↗
  5. KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Co-author DOI 10.1016/j.ccell.2023.07.002↗
  6. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Co-author DOI 10.1016/j.devcel.2023.07.025↗
  7. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.06.011↗
  8. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-018-0196-2↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kathleen M. McAndrews · 7 shared papers, 2022–2026 · strength 1.15
  2. Raghu Kalluri · 7 shared papers, 2022–2026 · strength 1.15
  3. Anirban Maitra · 5 shared papers, 2023–2026 · strength 0.81
  4. Timothy Paul Heffernan · 3 shared papers, 2023–2026 · strength 0.48
  5. Paola A. Guerrero · 3 shared papers, 2023–2026 · strength 0.48
  6. Yang Chen · 3 shared papers, 2022–2024 · strength 0.48
  7. Sujuan Yang · 3 shared papers, 2022–2025 · strength 0.45
  8. Huamin Wang · 2 shared papers, 2022–2024 · strength 0.33
  9. Haoqiang Ying · 2 shared papers, 2023 · strength 0.28
  10. Aislyn P. Schalck · 1 shared paper, 2026 · strength 0.20
  11. Navid Sobhani · 1 shared paper, 2026 · strength 0.20
  12. Vincent Bernard · 1 shared paper, 2026 · strength 0.20
  13. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.18
  14. Elizabeth J. Shpall · 1 shared paper, 2025 · strength 0.18
  15. Mayela Carolina Mendt Vilchez · 1 shared paper, 2025 · strength 0.18
  16. Valerie S. Kalluri · 1 shared paper, 2025 · strength 0.18
  17. Gauri Rajani Varadhachary · 1 shared paper, 2025 · strength 0.18
  18. Brandon George Smaglo · 1 shared paper, 2025 · strength 0.18
  19. Shubham Pant · 1 shared paper, 2025 · strength 0.18
  20. Benson Chellakkan Selvanesan · 1 shared paper, 2025 · strength 0.15
  21. Fredrik I. Thege · 1 shared paper, 2025 · strength 0.15
  22. Clint A. Stalnecker · 1 shared paper, 2025 · strength 0.15
  23. Channing J. Der · 1 shared paper, 2025 · strength 0.15
  24. Ronald Anthony Depinho · 1 shared paper, 2023 · strength 0.15
  25. Michael P. Kim · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.